Ignite Creation Date:
2024-05-06 @ 5:53 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05469178
Status:
RECRUITING
Last Update Posted:
2023-10-10
First Post:
2022-07-19
Brief Title:
A Study to Investigate the Safety Tolerability and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
Sponsor:
BerGenBio ASA
Organization:
BerGenBio ASA
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12-14
Start Date Type:
ACTUAL
Primary Completion Date:
2025-08-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-08-11
Completion Date Type:
ESTIMATED
First Submit Date:
2022-07-19
First Submit QC Date:
July 19 2022
Study First Post Date:
2022-07-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-06
Last Update Post Date:
2023-10-10
Last Update Post Date Type:
ACTUAL